Rep. Donald G. Davis

Maddy summaryHR 5840, the Transportation Security Screening Modernization Act of 2024, simplifies the process for transportation workers to obtain multiple TSA security credentials. It requires the TSA to allow individuals to apply for and renew programs like the TWIC (Transportation Worker Identification Credential) and HAZMAT Endorsement through a single enrollment at any TSA center, with a combined fee lower than separate applications. The bill mandates coordinated expiration dates for all credentials and ensures state-issued commercial driver's licenses reflect the correct HAZMAT endorsement validity. These changes aim to reduce duplication and costs for workers needing multiple security clearances. The TSA must implement these changes within two years and publish details online.

Maddy summaryHR 5819, the COMPLETE Care Act, incentivizes Medicare primary care providers to integrate behavioral health services by increasing payments for specific services (like mental health and substance use disorder support) during 2025-2027. Providers using designated HCPCS codes for integrated care would receive 125-175% of standard payment rates, with the percentage declining annually. The bill also requires these providers to report on integration quality measures and mandates technical assistance for practices adopting integrated models, funded through new appropriations for 2024-2027. It directly affects Medicare-participating primary care practices serving beneficiaries needing mental health or substance use services.

Maddy summaryThis bill expands Medicare coverage for in-home administration of intravenous immune globulin (IVIG) to include treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), effective January 1, 2026. It amends Medicare law to add these conditions to the list of covered primary immune deficiency diseases, directly affecting Medicare beneficiaries with CIDP or MMN who currently lack coverage for in-home IVIG. The bill also allows Medicare payment adjustments based on whether IVIG is used for primary immune deficiency or these new neurological conditions, as determined by the Secretary through formal rulemaking. This creates a specific policy change to broaden access for two neurological conditions previously excluded from in-home IVIG coverage.

Maddy summaryThis bill provides continuing appropriations for federal government operations through January 11, 2024, ensuring funding for ongoing programs and activities. It includes $16 billion for disaster relief and over $21 billion in supplemental funding for Ukraine assistance, covering military aid, economic support, and humanitarian programs. The bill also extends funding for community health centers, Federal Aviation Administration programs, and the Temporary Assistance for Needy Families program through the same date. These funding measures maintain government operations and support critical domestic and international programs during the fiscal year.

Maddy summaryThis bill requires health insurance plans (both private and Medicare) to cover routine patient costs for children with rare pediatric diseases participating in approved clinical trials, even when care is provided by non-network providers. Specifically, it mandates that insurers apply the same copay or coinsurance rate for non-participating providers as they would for in-network providers during clinical trial participation. The law expands the definition of "routine costs" to include consultation and referral services related to these trials and updates Medicare coverage rules to align with this requirement. These changes apply to plans beginning January 1, 2024, directly affecting families of children with rare pediatric cancers enrolled in qualifying clinical trials.

Maddy summaryThis bill makes permanent Medicare coverage for telehealth services provided by Federally Qualified Health Centers (FQHCs) and Rural Health Clinics (RHCs), including audio-only visits. It directly affects Medicare beneficiaries who use these services and the FQHCs/RHCs delivering them by removing location restrictions - allowing telehealth visits to occur regardless of the patient's geographic location. Key provisions include permanently covering audio-only telehealth (previously temporary), treating telehealth visits as equivalent to in-person visits for payment, and ensuring costs for telehealth are included in FQHC/RHC payment calculations. These changes simplify access to telehealth for rural and underserved communities while maintaining consistent Medicare reimbursement for providers.

Maddy summaryThe CARE for Moms Act aims to reduce maternal mortality in the United States by improving healthcare access and quality for pregnant and postpartum women, with specific attention to racial disparities. Key provisions include requiring 12-month continuous Medicaid coverage for postpartum individuals (up from 60 days), expanding oral health coverage during pregnancy, and funding State-Based Perinatal Quality Collaboratives through $35 million annual grants. The bill specifically targets the higher maternal mortality rates faced by Black women, who are about 3 times more likely to die from pregnancy-related causes than White women. It also includes provisions for doula services, rural mobile health units, and improved data collection on maternal health outcomes.

Maddy summaryThe ORPHAN Cures Act amends the Drug Price Negotiation Program under the Social Security Act to clarify how orphan drugs (medications for rare diseases affecting fewer than 200,000 people in the U.S.) are treated. It ensures that periods when a drug was designated as an orphan drug are excluded from the time calculation used to determine when the drug can no longer be excluded from price negotiations. The bill also updates the definition to allow a single drug to be designated for multiple rare diseases, rather than just one. This change provides clearer rules for manufacturers and the government regarding orphan drug exclusions in the program.

Maddy summaryThe Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.

Maddy summaryThe Preserving Access to Home Health Act of 2023 repeals a 2018 payment adjustment for Medicare home health agencies, restoring prior payment rates for 2024 and subsequent years. It requires the Medicare Payment Advisory Commission (MedPAC) to analyze how home health agencies' financial performance affects access to care, including reviewing spending and utilization data across Medicare, Medicaid, and other payers. Starting in 2025, the bill mandates home health agencies to report detailed data on visit volumes and payments by payer source (Medicare, Medicaid, private insurers) through updated cost reports. This data will help MedPAC assess payment policy impacts on access to home health services for Medicare beneficiaries.